FDA Approves Phathom’s Voquezna Triple and Dual PAK

Phathom Pharmaceuticals says FDA approved Voquezna Triple Pak and Dual Pak for treatment of Heliobacter pylori infection in adults.

• Shares rose 8.7% in post-market trading
• Phathom in-licensed the U.S., European, and Canadian rights to vonoprazan, an ingredient in Voquezna, from Takeda

NOTE

• Phathom Pharmaceuticals Inc. rose 12.4% in postmarket trading to $16.45 as of 5:46 p.m. New York time
  • The average 12-month price target of $52.67 is 220.2% above the current price
  • 6 buys, 1 holds, 0 sells

To view the source of this information, click here

To contact the reporter on this story:
Jim Silver in New York at ...